Boehringer adds to NASH pipeline with $870 million deal

1 July 2019
boehringer_building_large

Germany’s Boehringer Ingelheim and South Korean firm Yuhan Corp (000100: KS) today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of non-alcoholic C (NASH) and related liver diseases that combines GLP-1 and FGF21 activity in one molecule.

The collaboration brings together Yuhan’s expertise in FGF21 biology, obesity and NASH with family-owned Boehringer Ingelheim’s pharmaceutical expertise and commitment to bringing innovative medicines to patients with cardiometabolic diseases.

News of the deal saw Yuhan’s shares close up 2.86% at 251,500 won today, having hit an intraday high of 267,500 won, despite the fact that research efforts on NASH candidates have seen a string of disappointments so far.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology